Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ADTrust real-world study of lebrikizumab in moderate-to-severe atopic dermatitis
NL-OMON57599Phase 4Not yet recruiting
- Sponsor
- Almirall
- Start
- May 2025
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of lebrikizumab in atopic dermatitis (AD), sponsored by Almirall. Primary endpoint: Overall health-related well-being. Planned start May 2025; status: not yet recruiting.
02
Drugs
lebrikizumab
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on NL-OMON57599.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON57599.